CLINICAL EFFICACY OF LEUPROLIDE ACETATE AND COMBINED TREATMENT WITH ESTRAMUSTINE FOR ADVANCED PROSTATE CANCER
نویسندگان
چکیده
منابع مشابه
Abiraterone acetate: redefining hormone treatment for advanced prostate cancer.
Prostate cancer has long since been recognised as being hormonally driven via androgen receptor signalling. Abiraterone acetate (AA) is a rationally designed CYP17 inhibitor that blocks the conversion of androgens from non-gonadal precursors effectively, thus reducing testosterone to undetectable levels. AA has recently been proved to extend survival for men with metastatic castration-resistant...
متن کاملDegarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis
Background: Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. We performed a systematic review to compare safety, efficacy and effectiveness of degarelix, a new gonadotropin-releasing hormone (GnRH) antagonist (blocker), versus gonadotropin-releasing hormone (GnRH) agonists. Methods: MEDLINE, Web of Science and the Cochrane librar...
متن کاملHigh efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
BACKGROUND To assess the activity of docetaxel in combination with hormonal therapy in preclinical models of prostate cancer. MATERIALS AND METHODS Since prostate cancer has a predilection for the bone, we assessed the antitumor activity of docetaxel in in vivo models of both bone metastasis and localized prostate cancer, using MDA PCa 2b and PC3 cells in SCID mice. RESULTS Dramatic antitum...
متن کاملDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
BACKGROUND Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer. METHODS We randomly assigned 770 men to one of two treatments, each given in 21-day cycles: 280 mg of estramustin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Japanese Journal of Urology
سال: 2001
ISSN: 0021-5287,1884-7110
DOI: 10.5980/jpnjurol1989.92.682